本文選題：口腔扁平苔蘚　切入點(diǎn)：糜爛型口腔扁平苔蘚　出處：《大連醫(yī)科大學(xué)》2017年碩士論文

【摘要】：背景及目的:口腔扁平苔蘚是一種常見(jiàn)的口腔黏膜慢性炎癥疾病,其發(fā)病機(jī)制目前尚不明確,病損可同時(shí)累及皮膚和黏膜。其中糜爛型扁平苔蘚因其經(jīng)常在患者睡覺(jué)、進(jìn)食、說(shuō)話及其他的日�；顒�(dòng)中出現(xiàn)疼痛,而對(duì)患者的生活造成嚴(yán)重的影響。有研究表明,用他克莫司來(lái)治療糜爛型口腔扁平苔蘚是安全并且有效的。重組人表皮生長(zhǎng)因子凝膠可誘導(dǎo)細(xì)胞增殖、移行和分化,從而促進(jìn)基底膜的形成,同時(shí)也可抑制T細(xì)胞的增殖。本實(shí)驗(yàn)的目的在于對(duì)比他克莫司與重組人表皮生長(zhǎng)因子凝膠治療糜爛型口腔扁平苔蘚臨床效果。方法:本實(shí)驗(yàn)的患者均來(lái)自大連醫(yī)科大學(xué)附屬第一醫(yī)院口腔門(mén)診。30名被口腔專科醫(yī)生臨床診斷為糜爛型口腔扁平苔蘚的患者被隨機(jī)分為三組,每組患者10名。A組給予他克莫司和白芍總苷膠囊;B組給予重組人表皮生長(zhǎng)因子凝膠和白芍總苷膠囊;C組(對(duì)照組)給予氯己定漱口液及白芍總苷膠囊。在為期三個(gè)月的治療期內(nèi),患者每月復(fù)診一次,同時(shí)檢查患者的疼痛程度、糜爛程度和病損面積的改變。結(jié)果:共有30名患者參與了此項(xiàng)試驗(yàn),其中63%為女性患者、37%為男性,平均年齡51歲。在3個(gè)月的用藥期內(nèi),A組和B組患者在疼痛程度的減輕方面無(wú)明顯差異。A組和C組患者在疼痛程度的減輕方面有明顯差異。B組和C組患者在疼痛程度的減輕方面有明顯差異。在3個(gè)月的用藥期內(nèi),A組和B組患者在糜爛程度減輕和病損面積縮小方面無(wú)明顯差異。A組和C組患者在糜爛程度減輕和病損面積縮小方面有明顯差異。B組和C組患者在糜爛程度減輕和病損面積縮小方面有明顯差異。結(jié)論:在三個(gè)月的實(shí)驗(yàn)期內(nèi),他克莫司和重組人表皮生長(zhǎng)因子凝膠均可減輕疼痛、減小病變范圍。他克莫司和重組人表皮生長(zhǎng)因子凝膠在減輕疼痛程度、和減小病損范圍方面沒(méi)有明顯差異。
[Abstract]:Background & objective: oral lichen planus (OLP) is a common chronic inflammatory disease of oral mucosa. Pain in speech and other daily activities has a serious impact on the lives of patients. It is safe and effective to treat erosive oral lichen planus with tacrolimus. Recombinant human epidermal growth factor gel can induce cell proliferation, migration and differentiation, thus promoting the formation of basement membrane. The aim of this experiment was to treat erosive oral lichen planus with bitacrolimus and recombinant human epidermal growth factor gel. Methods: all patients in this study were from Dalian medicine. A total of 30 patients with erosive oral lichen planus (OLP) were randomly divided into three groups in the oral outpatient clinic of the first affiliated Hospital of the University of Science and Technology, which was clinically diagnosed as erosive oral lichen planus by an oral specialist. 10 patients in each group were given tacrolimus and total paeony glucoside capsule group B with recombinant human epidermal growth factor gel and total paeony glycoside capsule group C (control group) with chlorhexidine gargle and total paeony glycoside capsule. Within a month of treatment, The patients were reviewed once a month, and their pain, erosion and lesion area were examined. Results: a total of 30 patients participated in the study, 63 percent of whom were women and 37 percent of whom were men. The average age was 51 years. There was no significant difference in pain relief between group A and group B. there was a significant difference between group A and group C. there was a significant difference in pain between group B and group C. There was no significant difference in erosion degree and lesion area between group A and group B. there was no significant difference between group A and group C. patients in group A and group C reduced the degree of erosion and the area of lesion. There were significant differences between group B and group C. there were significant differences in erosive degree and lesion area between group B and group C. conclusion: during the three-month experimental period, there were significant differences between the two groups. Tacrolimus and recombinant human epidermal growth factor gel could reduce pain and lesion range, but tacrolimus gel and recombinant human epidermal growth factor gel had no significant difference in reducing pain and extent of lesion.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R781.5
，

本文編號(hào)：1698207